|
Marsha Moses, PhD, interim director, Vascular Biology Program at Children's Hospital Boston, was elected to the Institute of Medicine (IOM) on Monday, Oct. 13. Election to the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
"This esteemed honor has been awarded to one of Children's finest and most visionary researchers," said James Mandell, MD, president and CEO, Children's Hospital Boston. "The work Dr. Moses has done to advance research in vascular biology, particularly in the field of biomarkers, is truly impressive."
Dr. Moses and her team of researchers have made substantial scientific contributions by identifying and characterizing the biochemical and molecular mechanisms underlying the regulation of angiogenesis during tumor progression. Her lab has also developed a number of sensitive and specific non-invasive urine tests for different cancers, as part of their long term Urinary Proteomics Initiative. These cancer tests are based on the lab's work focused on the detection of biomarker proteins purified from the urine of cancer patients. A number of these urine tests are currently in clinical testing as potential cancer diagnostics and prognostics.
"It is a great pleasure to welcome these distinguished and influential individuals to the Institute of Medicine," said IOM President Harvey V. Fineberg. "Members are elected through a highly selective process that recognizes people who have made major contributions to the advancement of the medical sciences, health care, and public health."
|
